Sector
PharmaceuticalsOpen
₹814.7Prev. Close
₹814Turnover(Lac.)
₹46,564.2Day's High
₹869.7Day's Low
₹809.4552 Week's High
₹052 Week's Low
₹0Book Value
₹0Face Value
₹5Mkt Cap (₹ Cr.)
36,598.55P/E
0EPS
0Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2014 | Dec-2012 | Dec-2011 | Dec-2010 |
|---|---|---|---|---|
Equity Capital | 212.16 | 212.57 | 211.67 | 217.12 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 884.83 | 1,709.51 | 1,713.17 | 4,915.28 |
Net Worth | 1,096.99 | 1,922.08 | 1,924.84 | 5,132.4 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2014 | Dec-2012 |
|---|---|---|
Revenue | 6,864.93 | 6,303.54 |
yoy growth (%) | 8.9 | |
Raw materials | -2,872.84 | -2,288.41 |
As % of sales | 41.84 | 36.3 |
Employee costs | -1,274.72 | -1,019.58 |
| Y/e 31 Mar( In .Cr) | Mar-2014 | Dec-2012 |
|---|---|---|
Profit before tax | -366.88 | 216.94 |
Depreciation | -280.17 | -186.16 |
Tax paid | -30.57 | 1.94 |
Working capital | -1,471.1 | |
Other operating items |
| Y/e 31 Mar | Mar-2014 | Dec-2012 |
|---|---|---|
Growth matrix (%) | ||
Revenue growth | 8.9 | |
Op profit growth | -173.25 | |
EBIT growth | -64.94 | |
Net profit growth | 441.45 |
| Particulars (Rupees in Crores.) | Mar-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 |
|---|---|---|---|---|---|
Gross Sales | 13,040.32 | 10,604.19 | 12,252.88 | 9,970 | 8,550.66 |
Excise Duty | 0 | 0 | 0 | 0 | 15.22 |
Net Sales | 13,040.32 | 10,604.19 | 12,252.88 | 9,970 | 8,535.45 |
Other Operating Income | 228.16 | 197.47 | 206.83 | 259.51 | 425.32 |
Other Income | 182.83 | 159.13 | 273.17 | 182.19 | 1,097.47 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
Takashi Shoda
Chairman
Tsutomu Une
Director
Rajesh V Shah
Company Secretary
S K Patawari
Managing Director & CEO
Arun Sawhney
Director
Anthony H Wild
Director
Akihiro Watanabe
Director
Kazunori Hirokawa
Director
Percy K Shroff
Plot No 90,
Sector 32,
Haryana - 122001
Tel: 91-0124-4135000
Website: http://www.ranbaxy.com
Email: -
2E/8,
Blazeflash House, Jhandewalan Extn,
New Delhi - 110055
Tel: 91-011-51540060-63
Website: www.alankit.com
Email: info@alankit.com
Summary
Ranbaxy Laboratories Ltd, Indias largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines...
Read More
Reports by Ranbaxy Laboratories Ltd Merged
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.